| 000 | 01635 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513113349.0 | ||
| 264 | 0 | _c19970415 | |
| 008 | 199704s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRubenstein, E B | |
| 245 | 0 | 0 |
_aRandomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group. _h[electronic resource] |
| 260 |
_bCancer _cMar 1997 |
||
| 300 |
_a1216-24 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAntiemetics _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aDoxorubicin _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aQuinolizines _xadministration & dosage |
| 700 | 1 | _aGralla, R J | |
| 700 | 1 | _aHainsworth, J D | |
| 700 | 1 | _aHesketh, P J | |
| 700 | 1 | _aGrote, T H | |
| 700 | 1 | _aModiano, M R | |
| 700 | 1 | _aKhojasteh, A | |
| 700 | 1 | _aKalman, L A | |
| 700 | 1 | _aBenedict, C R | |
| 700 | 1 | _aHahne, W F | |
| 773 | 0 |
_tCancer _gvol. 79 _gno. 6 _gp. 1216-24 |
|
| 999 |
_c9057801 _d9057801 |
||